首页> 外国专利> MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-EXPRESSING CANCER CELL VACCINE AND METHODS OF USE FOR PRODUCING INTEGRATED IMMUNE RESPONSES

MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-EXPRESSING CANCER CELL VACCINE AND METHODS OF USE FOR PRODUCING INTEGRATED IMMUNE RESPONSES

机译:主要的组织相容性复合体II类表达癌细胞疫苗和用于产生综合免疫应答的方法

摘要

Provided are modified cancer cells that are modified to co-express class II trans-activator (CIITA), and an immuno-stimulatory molecule. The immuno-stimulatory molecule is OX-40-ligand or 4-lBB-Ligand. Methods of making the cells are provided by introducing polynucleotides encoding the CIITA and the immune-stimulatory molecule into cancer cells. Methods of stimulating humoral and cell-mediated immune responses by administering the modified cancer cells, or polynucleotides encoding the CIITA and immune-stimulatory molecules are also provided. These approaches can be used to stimulate an immune response against any of a wide variety of cancer antigens.
机译:提供了改性癌细胞,其被修饰为Co-Express II类反式激活剂(Ciita)和免疫刺激分子。免疫刺激分子是Ox-40-配体或4-LBB-配体。通过将编码细胞素和免疫刺激分子的多核苷酸引入癌细胞来提供制备细胞的方法。还提供了通过施用修饰的癌细胞或编码CIITA和免疫刺激分子的多核苷酸来刺激体液和细胞介导的免疫应答的方法。这些方法可用于刺激对各种癌症抗原的免疫应答。

著录项

  • 公开/公告号EP3824097A1

    专利类型

  • 公开/公告日2021-05-26

    原文格式PDF

  • 申请/专利权人 HEALTH RESEARCH INC.;

    申请/专利号EP20190841026

  • 申请日2019-07-22

  • 分类号C12Q1/68;C12N5/07;C12N5/071;C12N5/09;C12N5/16;C12N15/79;C12N15/85;C12N15/86;A61K38/16;A61K38/19;

  • 国家 EP

  • 入库时间 2022-08-24 19:00:14

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号